United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 8,000 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR – Get Rating) CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Friday, January 6th. The stock was sold at an average price of $276.29, for a total transaction of $2,210,320.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $35,917.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $264.97 on Tuesday. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of 18.03, a PEG ratio of 1.63 and a beta of 0.62. United Therapeutics Co. has a 12 month low of $158.38 and a 12 month high of $283.09. The firm’s 50-day moving average is $270.28 and its 200 day moving average is $239.76. The company has a current ratio of 9.68, a quick ratio of 9.39 and a debt-to-equity ratio of 0.18.

United Therapeutics (NASDAQ:UTHR – Get Rating) last issued its quarterly earnings results on Wednesday, November 2nd. The biotechnology company reported $4.91 EPS for the quarter, beating the consensus estimate of $3.57 by $1.34. The company had revenue of $516.00 million for the quarter, compared to the consensus estimate of $492.92 million. United Therapeutics had a net margin of 38.03% and a return on equity of 16.63%. Research analysts predict that United Therapeutics Co. will post 16.63 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Wedbush boosted their price target on shares of United Therapeutics from $250.00 to $305.00 in a research note on Thursday, November 3rd. Morgan Stanley boosted their price target on shares of United Therapeutics from $322.00 to $330.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 6th. The Goldman Sachs Group assumed coverage on shares of United Therapeutics in a research note on Monday, December 5th. They issued a “sell” rating and a $230.00 price target on the stock. HC Wainwright upped their target price on shares of United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a research report on Thursday, November 3rd. Finally, StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 3rd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $282.00.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Cookson Peirce & Co. Inc. grew its holdings in United Therapeutics by 0.8% during the 3rd quarter. Cookson Peirce & Co. Inc. now owns 5,196 shares of the biotechnology company’s stock valued at $1,088,000 after purchasing an additional 43 shares during the last quarter. Formidable Asset Management LLC grew its stake in United Therapeutics by 2.2% in the 3rd quarter. Formidable Asset Management LLC now owns 2,330 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 51 shares in the last quarter. Fifth Third Bancorp grew its stake in United Therapeutics by 2.2% in the 2nd quarter. Fifth Third Bancorp now owns 2,426 shares of the biotechnology company’s stock worth $572,000 after acquiring an additional 53 shares in the last quarter. Hancock Whitney Corp grew its stake in United Therapeutics by 0.4% in the 3rd quarter. Hancock Whitney Corp now owns 12,183 shares of the biotechnology company’s stock worth $2,550,000 after acquiring an additional 53 shares in the last quarter. Finally, Arizona State Retirement System grew its stake in United Therapeutics by 0.5% in the 2nd quarter. Arizona State Retirement System now owns 12,231 shares of the biotechnology company’s stock worth $2,882,000 after acquiring an additional 57 shares in the last quarter. 95.63% of the stock is currently owned by institutional investors.

About United Therapeutics

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.